SPECT

Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Southeast United States

Retrieved on: 
Martedì, Gennaio 10, 2023
Partnership, Drug development, Government budget balance, Research, LMI, Brain, Alzheimer's disease, Dementia, Disease, Patient, SPECT, Physician, PET, Jubilant, Neurodegeneration, Medical imaging

BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States. Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA. The first doses will be available from January 18th, 2023.

Key Points: 
  • BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States.
  • Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA.
  • "With the addition of Jubilant's Norcross Radiopharmacy to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain.
  • "It is a great pleasure to have signed this important manufacturing and distribution agreement with Life Molecular Imaging" – declares Renato Leite, President at Jubilant Radiopharmacies.

Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99

Retrieved on: 
Mercoledì, Dicembre 21, 2022
Patient, BR2, SPECT, Isotopes of molybdenum, Risk, Renewable energy, Medical imaging

PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20 December, Curium’s supply of molybdenum-99 (Mo-99) and iodine-131 is continuing as usual.

Key Points: 
  • PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20 December, Curium’s supply of molybdenum-99 (Mo-99) and iodine-131 is continuing as usual.
  • This follows a shortage of Mo-99 that the entire global nuclear medicine industry experienced in November of this year.
  • A reliable supply of Mo-99 is critically important for the 40 million patients every year around the world who undergo SPECT scans to diagnose life-critical diseases.
  • With the outlook of the global reactors’ schedules similar to that of previous years, for 2023 we foresee no further supply chain challenges.”
    Despite the recent global shortage of Mo-99, with an industry supply chain track-record that has proven to be resilient over the past ten years, Curium is committed to ensuring that its operations remain steadily reliable through massive investments so it can serve its 14 million patients annually.

2022 HospeTrack Hospital Intelligence Insights for Bahrain - Featuring Fresenius Medical Care, Drager, Philips Healthcare and Siemens Healthineers Among Others - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Dicembre 19, 2022
Health, Other Health, Universe, Hospital, Total, Dräger (company), Public, MRI, Degenerative disease, SPECT, Worksheet, Fresenius Medical Care, GPS, Siemens Healthineers, ORS, Growth, Size, COVID-19, CT, Kingdom, ICU, Incubator, Room, Non-communicable disease, Private sector, Teaching hospital, Philips, GE Healthcare, Critical care, Canon Medical Systems Corporation, Type, Hitachi, Cath lab, PET, Investment, Data, Physician, Microsoft Excel, Cardiology, Research, Google Images, Bed, GCC, Cryptocurrency, Healthcare, Health insurance, Medical imaging, Medical device, Toshiba

Key medical device companies featured in the dataset include: Fresenius Medical Care, Drager, Philips Healthcare, Siemens Healthineers, GE Healthcare, Toshiba (Canon Medical Systems), Hitachi, Mindray.

Key Points: 
  • Key medical device companies featured in the dataset include: Fresenius Medical Care, Drager, Philips Healthcare, Siemens Healthineers, GE Healthcare, Toshiba (Canon Medical Systems), Hitachi, Mindray.
  • HospeTrack Hospital Intelligence for Bahrain, Guidance & Hospital Segmentation
    Provides brief methodology of research along with extensive detail around total coverage of hospitals in Bahrain, by type of hospital.
  • HospeTrack Hospital Intelligence for Bahrain, Insight Summary
    3.4 IB Penetration Summary for Bahrain by Care Level of Hospital, 2022
    4.
  • HospeTrack Hospital Intelligence for Bahrain, IB Base File
    Provides the raw data for all installed base equipment by account in Bahrain.

Medical Metaverse Company, apoQlar, Receives FDA 510(k) Clearance for its Mixed Reality Surgical Planning Platform, VSI HoloMedicine®

Retrieved on: 
Lunedì, Dicembre 5, 2022
Physician, CBCT, PET, MRI, Learning, Patient, VSI, Gulf Coast State College, FDA, 3D, HoloLens 2, SPECT, Surgeon, Microsoft HoloLens, Microsoft, HSA, CE, HMD, Medical device, Medical imaging

Following this major achievement, apoQlar is now raising a Series A round, its first ever fundraising campaign, to scale VSI Holomedicine as the foundation of modern surgical care.

Key Points: 
  • Following this major achievement, apoQlar is now raising a Series A round, its first ever fundraising campaign, to scale VSI Holomedicine as the foundation of modern surgical care.
  • VSI HoloMedicine gives surgeons an almost "x-ray vision" perspective in surgical planning processes using 3D holographic technology.
  • apoQlar developed an affordable medical metaverse technology, VSI HoloMedicine, that brings the crucial third dimension to surgical planning, remote consultation, patient education and medical training.
  • VSI HoloMedicine holds FDA 510(k), CE Class I and HSA Class A medical certifications for clinical use in 30 countries.

Medical Metaverse Company, apoQlar, Receives FDA 510(k) Clearance for its Mixed Reality Surgical Planning Platform, VSI HoloMedicine®

Retrieved on: 
Mercoledì, Novembre 23, 2022
Physician, CBCT, PET, MRI, Learning, Patient, VSI, Gulf Coast State College, FDA, 3D, HoloLens 2, SPECT, Surgeon, Microsoft HoloLens, Microsoft, HSA, CE, HMD, Medical device, Medical imaging

Following this major achievement, apoQlar is now raising a Series A round, its first ever fundraising campaign, to scale VSI Holomedicine as the foundation of modern surgical care.

Key Points: 
  • Following this major achievement, apoQlar is now raising a Series A round, its first ever fundraising campaign, to scale VSI Holomedicine as the foundation of modern surgical care.
  • VSI HoloMedicine gives surgeons an almost "x-ray vision" perspective in surgical planning processes using 3D holographic technology.
  • apoQlar developed an affordable medical metaverse technology, VSI HoloMedicine, that brings the crucial third dimension to surgical planning, remote consultation, patient education and medical training.
  • VSI HoloMedicine holds FDA 510(k), CE Class I and HSA Class A medical certifications for clinical use in 30 countries.

Curium’s Customers to Benefit From Mo-99 Production Restart

Retrieved on: 
Mercoledì, Novembre 23, 2022
Curium, HFR, Diagnosis, Nuclear medicine, Molybdenum, Hospital, Patient, Maintenance, HEU, Enriched uranium, Thallium, LEU, Isotopes of molybdenum, SPECT, Investment, Uranium, Medical imaging

Re-establishing a reliable supply of Mo-99 is critically important for the 40 million patients a year who undergo Tc-99m based SPECT scans to diagnose life-critical diseases.

Key Points: 
  • Re-establishing a reliable supply of Mo-99 is critically important for the 40 million patients a year who undergo Tc-99m based SPECT scans to diagnose life-critical diseases.
  • To address this supply shortage, Curium was forced to reroute, adjust, and in some cases postpone customer orders, with production capacity for some cyclotron products such as Thallium pushed to its maximum, and Curiums PET Europe business unit supporting with additional capacity where possible (e.g.
  • Providing additional generators over the coming weeks to help decrease the patient backlog that may have built up in November.
  • While this scheduling ensures the best possible coverage for the reliable production of these radionuclides, it cannot predict unplanned outages.

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Retrieved on: 
Martedì, Novembre 22, 2022
Hypersensitivity, Kidney, Multiple system atrophy, Risk, Defecation, Pregnancy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth, Miscarriage, Iodine, Itch, PSP, Dizziness, Urination, Dementia, Lactation, Alzheimer's disease, Placenta, Nausea, Breast milk, Caregiver, Patient, Radiation, Vertigo, Thyroid, Frontotemporal dementia, Medicine, SPECT, FDA, Diagnosis, Degenerative disease, PET, Food, DLB, Nuclear medicine, Disease, Radiopharmaceutical, Failure, Neoplasm, Safety, Headache, Dopamine, Administration, Milk, Hippocampal sclerosis, GE, Scan (company), Regulation, MSA, Injection, PD, Lewy body, Tremor, Xerostomia, Excipient, Infant, Medical imaging, Pharmaceutical industry, Vaccine, Birth control, Ioflupane (123I), Parkinsonism, PS

Curium will update Ioflupane I 123 Injection important risk information to include the new safety information at the time of labeling implementation.

Key Points: 
  • Curium will update Ioflupane I 123 Injection important risk information to include the new safety information at the time of labeling implementation.
  • The expected new indication enables clinicians to use Ioflupane I 123 Injection to help differentiate DLB from other forms of dementia.
  • Curium has years of experience in this disease state as our Ioflupane I 123 Injection product in Europe launched with this indication.
  • The kidney excretes Ioflupane I 123 Injection; patients with severe renal impairment may have increased radiation exposure and altered Ioflupane I 123 Injection images
    It is unknown whether or not ioflupane is dialyzable.

HospeTrack Hospital Intelligence for Myanmar 2022: Opportunities to be Found in Public & Private Secondary Care Facilities - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 24, 2022
Hospitals, Health Technology, Health, Hospital, ICU, Jaundice, Light, Sepsis, NICU, Joint Commission on Allied Health Personnel in Ophthalmology, Bed, Life expectancy, PET, Incubator, MRI, India and the World Bank, SPECT, Private, Cath lab, Woman, World Bank, GDP, Infant, Physician, Asphyxia, Specialist, Ministry, ORS, Education, Degenerative disease, CT, Health, Risk, ASEAN, Healthcare Facilities Accreditation Program, Chin, Medicine, Ultrasound, Mammography, Dialysis

With a fragile economy, growth opportunities for medical devices remain restricted in Myanmar.

Key Points: 
  • With a fragile economy, growth opportunities for medical devices remain restricted in Myanmar.
  • As of 2021-22, Myanmar has 1,063 healthcare facilities, with 948 public hospitals, 106 private hospitals, and 9 military hospitals.
  • According to this HospeTrack Hospital Intelligence for Myanmar, market opportunities for the next 5-10 years lie in secondary care public and private facilities for neonatal care equipment.
  • Assess and differentiate based on size of hospital - General hospital, Station hospital,100-bedded, 50-bedded, 25-bedded, Specialist hospital, Private hospital and Imaging centers
    1,063 hospitals and Imaging centers in Myanmar listed by city, region, latitude and longitude and Zip Code

Australia HospeTrack Hospital Intelligence Report 2022: Upcoming Developments in Cancer Care Infrastructure to Drive Demand in Australia's Medical Device Industry - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Novembre 23, 2022
Hospitals, Health, Oncology, Prevalence, ICU, Medical Research Future Fund, Government, PET/CT, DEXA, Bed, Molecular imaging, LINAC, Life expectancy, PET, Incubator, MRI, Cancer, SPECT, Medicare, Cath lab, Research, Nuclear medicine, Mental health, Diabetes, ORS, Conditional sentence, CT, Diagnosis, University, Incidence, Medical imaging, Health insurance, Ultrasound, Mammography, Dialysis

Upcoming developments in cancer care infrastructure to drive demand in Australian medical device industry.

Key Points: 
  • Upcoming developments in cancer care infrastructure to drive demand in Australian medical device industry.
  • As of 2021-22, Australia has 655 public healthcare facilities and 1,317 private facilities including imaging centers.
  • Australia has the highest number of cancer cases in the world, with an estimated 150,000 cases of cancer diagnosed each year.
  • According to this HospeTrack Hospital Intelligence for Australia, nuclear medicine and molecular imaging market is likely to present pockets of growth opportunities primarily related to the increasing prevalence of cancer.

HospeTrack Hospital Intelligence for Denmark: A Vision of Modernizing Hospital Infrastructure for a Sustainable Future - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 17, 2022
Hospitals, Health Technology, Health, Hospital, EUR, PET-CT, Health information management, Information technology, SPECT, Cath lab, Data, EMR, Medicine, Database, Renewable energy, Medical imaging

Denmark's healthcare market to be driven by the country's vision of modernizing hospital infrastructure for a sustainable future.

Key Points: 
  • Denmark's healthcare market to be driven by the country's vision of modernizing hospital infrastructure for a sustainable future.
  • As of 2021-22, Denmark has about 56 public and 58 private healthcare facilities including imaging centers spread throughout the five regions.
  • This HospeTrack is the largest database of hospital level medical equipment installed base data, currently available on the market.
  • The Denmark Total Hospital & Medical IB Mapping report was updated in 2022 and includes over 114 hospitals and imaging centers from the country with their health infrastructure detailed out.